Table 3.

Associations between having a KRAS mutation and each covariate of interest, reported as ORs with 95% Bonferroni CIs (corrected over all tested covariates), and effects of having a KRAS mutation on survival in each subgroup, reported as HRs with 95% Bonferroni CIs (corrected within each category of covariates), in the PDAC cohort.

	KRAS OR (Association with mutation occurrence and each covariate)	KRAS HR (Association with survival within each subgroup)
Institution
MSK	Referent	1.74 (1.13, 2.68)
DFCI	0.97 (0.39, 2.73)	2.90 (1.00, 8.42)
VICC	1.41 (0.40, 7.83)	2.79 (0.49, 15.82)
Sex
Male	Referent	2.05 (1.27, 3.31)
Female	1.26 (0.61, 2.66)	1.74 (1.04, 2.91)
Age (years)	1.03 (1.00, 1.07)
Race
White	Referent	1.89 (1.25, 2.85)
Asian	0.57 (0.15, 3.22)	1.03 (0.16, 6.73)
Black	1.83 (0.33, 37.60)	1.40 (0.09, 22.00)
Other	0.75 (0.05, 130.39)	NA
Stage
Stage I	Referent	2.86 (0.30, 27.70)
Stage II	2.43 (0.48, 9.43)	1.67 (0.92, 3.01)
Stage III	2.50 (0.40, 14.30)	3.30 (0.74, 14.77)
Stage IV	3.43 (0.66, 13.92)	1.67 (0.91, 3.05)
Histology
Adenocarcinoma	Referent	1.79 (1.25, 2.56)
Other	0.75 (0.18, 5.37)	7.26 (1.18, 44.63)